Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stevanato Group SpAFRA:87N +0.58%87 EV-to-EBITDA is 20.85 as of Sep. 09, 2026, which is 14% below its 10-year median of 24.18. GuruFocus rates FRA:87N with a GF Score™ of 87/100 and a GF Value™ of €22.30 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 516 Medical Devices & Instruments companies, Stevanato Group SpA ranks worse than 68.22% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Stevanato Group SpA's enterprise value is €5,133 Mil.
Stevanato Group SpA's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €246 Mil. Therefore, Stevanato Group SpA's EV-to-EBITDA for today is 20.85.
The historical rank and industry rank for Stevanato Group SpA's EV-to-EBITDA or its related term are showing as below:
FRA:87N'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.43 Med: 24.18 Max: 36.41
Current: 20.79
During the past 8 years, the highest EV-to-EBITDA of Stevanato Group SpA was 36.41. The lowest was 12.43. And the median was 24.18.
FRA:87N's EV-to-EBITDA is ranked worse than 68.22% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 13.965
vs FRA:87N: 20.79
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Stevanato Group SpA (FRA:87N) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Stevanato Group SpA's PE Ratio (TTM) for today is calculated as:
Stevanato Group SpA's share price for today is €17.40.
Stevanato Group SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.480.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Stevanato Group SpA's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:87N vs MMED, TFX, MMSI: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Stevanato Group SpA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stevanato Group SpA EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stevanato Group SpA's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Stevanato Group SpA's EV-to-EBITDA falls into.
Stevanato Group SpA's current Enterprise Value is €5,133 Mil.
Stevanato Group SpA's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €246 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stevanato Group SpA (FRA:87N) has a EV-to-EBITDA of 20.85 as of Sep. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Stevanato Group SpA. This is 14% below median its historical median of 24.18. Over the past decade, Stevanato Group SpA's EV-to-EBITDA has ranged from 12.43 to 36.41. According to the industry distribution chart, Stevanato Group SpA ranks #352 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 68.2%.
Is Stevanato Group SpA's EV-to-EBITDA too high?
Stevanato Group SpA's current EV-to-EBITDA of 20.85 is 14% below median its 10-year median of 24.18. Over the past 10 years, this metric has ranged from a low of 12.43 to a high of 36.41. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.97. Stevanato Group SpA's value of 20.85 is 49.3% above this industry median. Based on the distribution chart, Stevanato Group SpA ranks #352 out of 516 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Stevanato Group SpA has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stevanato Group SpA's EV-to-EBITDA compare to MMED and TFX?
According to the Medical Devices & Instruments industry distribution chart, Stevanato Group SpA ranks #352 out of 516 companies for EV-to-EBITDA. This places Stevanato Group SpA in the lower half of its industry. The industry median EV-to-EBITDA is 13.97. Stevanato Group SpA's value of 20.85 is 49.3% above this benchmark. Historically, Stevanato Group SpA's own EV-to-EBITDA has ranged from 12.43 to 36.41 over the past decade. While the company's 10-year median is 24.18 vs. the industry median of 13.97, Stevanato Group SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.97, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stevanato Group SpA's current EV-to-EBITDA of 20.85 is 49.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Stevanato Group SpA. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stevanato Group SpA's current EV-to-EBITDA is 20.85, which is 14% below median its own 10-year median of 24.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stevanato Group SpA stock overvalued right now?
Based on GuruFocus' analysis, Stevanato Group SpA (FRA:87N) is currently considered Modestly Undervalued. The stock's GF Value™ is €22.30, compared to a current price of €17.40 — trading 22% below its estimated fair value. The current EV-to-EBITDA is 20.85, which is 14% below median its 10-year median of 24.18 and 49.3% above the Medical Devices & Instruments industry median of 13.97. Stevanato Group SpA's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Stevanato Group SpA (FRA:87N), the current EV-to-EBITDA is 20.85 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stevanato Group SpA (FRA:87N) Overvalued in 2026?
Based on GuruFocus' analysis, Stevanato Group SpA stock appears to be undervalued.
The current stock price of €17.40 is trading 22% below its estimated GF Value™ of €22.30.
GuruFocus considers Stevanato Group SpA to be Modestly Undervalued.
Key valuation signals for FRA:87N:
EV-to-EBITDA: 20.85 (14% below median its 10-year median of 24.18)
GF Value™: €22.30 vs. price of €17.40 (22% below fair value)
Industry Position: 49.3% above the Medical Devices & Instruments median (#352 of 516)
No single metric tells the full story. See the FRA:87N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.
87GF Score
Get the complete analysis for FRA:87N
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:87N has been successfully added to your 
